Advice
following a full submission:
velaglucerase alfa (Vpriv®) is accepted for use within NHS Scotland.
Indication under review: Long-term enzyme replacement therapy in patients with type 1 Gaucher disease.
Velaglucerase alfa has been shown to be non-inferior to another enzyme replacement treatment in patients with type 1 Gaucher disease.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of velaglucerase. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland.
Download detailed advice130KB (PDF)
Medicine details
- Medicine name:
- velaglucerase (Vpriv)
- SMC ID:
- 681/11
- Indication:
- For long-term enzyme replacement therapy in patients with type 1 Gaucher disease.
- Pharmaceutical company
- Shire Pharmaceuticals
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 October 2012